2025 ICD-10-CM code E85.3
(Active) Effective Date: N/A Metabolic disorders - Metabolic disorders (E70-E88) Endocrine, Nutritional and Metabolic Diseases (E00-E89) Feed
Secondary systemic amyloidosis. This condition involves the buildup of abnormal proteins in various organs and tissues due to an underlying chronic inflammatory disease or long-term dialysis.
Medical necessity for the evaluation and management of secondary systemic amyloidosis is established by the presence of signs and symptoms suggestive of the condition in a patient with a predisposing condition such as a chronic inflammatory disease or long-term dialysis.Further testing and treatment are medically necessary when the diagnosis is confirmed or highly suspected.
Diagnosis involves evaluating family history, symptoms, physical examination, blood and urine tests (including tests for abnormal proteins, free light chains, and protein to creatinine ratio), liver and thyroid function tests, tissue biopsy, echocardiogram, CT scans, and MRI studies.
In simple words: Secondary systemic amyloidosis is a condition where abnormal proteins build up in your body's organs and tissues, usually because of another long-term illness like arthritis, tuberculosis, lupus, or some cancers. It can also happen in people who have been on dialysis for a long time. The symptoms depend on which organs are affected, but you might feel tired, weak, short of breath, or lose weight. You could also have a swollen tongue, numbness and tingling in your hands and feet, or skin problems.
Secondary systemic amyloidosis is a condition characterized by the accumulation of amyloid proteins in various organs and tissues secondary to an underlying chronic inflammatory disease (such as rheumatoid arthritis, tuberculosis, lupus, or certain cancers) or long-term dialysis. The symptoms vary depending on the affected organs but may include weakness, fatigue, shortness of breath, weight loss, enlarged tongue, numbness, tingling, pain and swelling in the extremities, irregular heartbeat, and skin lesions.Hemodialysis-associated amyloidosis (DRA) is a specific type of secondary systemic amyloidosis that primarily affects individuals undergoing long-term dialysis, leading to protein buildup in bones, joints, and tendons.
Example 1: A patient with a history of rheumatoid arthritis presents with fatigue, shortness of breath, and swelling in the ankles. After further investigation, including a tissue biopsy, they are diagnosed with secondary systemic amyloidosis., A patient undergoing long-term hemodialysis experiences joint pain and carpal tunnel syndrome.They are diagnosed with dialysis-related amyloidosis (DRA), a form of secondary systemic amyloidosis., A patient with long-standing tuberculosis develops kidney problems and peripheral neuropathy. A biopsy reveals amyloid deposits, confirming a diagnosis of secondary systemic amyloidosis.
Documentation should include evidence of the underlying chronic inflammatory disease or long-term dialysis, along with clinical findings, laboratory results (blood and urine tests, liver and thyroid function tests), biopsy results, and imaging findings (echocardiogram, CT, MRI).
- Specialties:Nephrology, Rheumatology, Hematology, Oncology, Cardiology
- Place of Service:Inpatient Hospital, Outpatient Hospital, Office, Independent Clinic